Ceryx Medical has initiated the first-in-human study of its Cysoni™ RSA Pacemaker’s potential to provide superior treatment for heart failure patients by boosting cardiac output through Respiratory Sinus Arrhythmia (RSA) inputs. According to the company’s announcement today, the first human patient has been enrolled for the RSA-Pace study at Waikato Hospital in Hamilton, New Zealand. The record-setting study focuses on evaluating the company’s technology in heart failure patients requiring temporary pacing after surgery.